**STROBE Statement—Checklist of items that should be included in reports of *retrospective studies***

| **Title and abstract** | **Manuscript Page Number** | **Recommendation** |
|------------------------|---------------------------|--------------------|
|                        | Ok, Page 1, Line 1-30, Section Abstract, Paragraph 1 | *(a)* Indicate the study’s design with a commonly used term in the title or the abstract  
* (b) Provide in the abstract an informative and balanced summary of what was done and what was found |

| **Introduction** | | |
|------------------|-------------------|-----|
| **Background/rationale** | Ok, Page 2 Line 2-Page 3 Line 10, Section Introduction, Paragraph 1-3 | Explain the scientific background and rationale for the investigation being reported |
| **Objectives** | Ok, Page 2 Line 2-Page 3 Line 10, Section Introduction, Paragraph 1-3 | State specific objectives, including any prespecified hypotheses |

| **Methods** | | |
|-------------|-------------------|-----|
| **Study design** | Ok, Page 4 Line 15-Page 5 Line 2, Section methods, Paragraph Patterns of failure analysis | Present key elements of study design early in the paper |
| **Setting** | Ok, Page 4 Line 4-13, Section methods, Paragraph Radiotherapy and follow-up | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
| **Participants** | Ok, Page 3 Line 17-Page 4 Line 2, Section methods, Paragraph Patients and treatment | *(a)* Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  
* (b) For matched studies, give matching criteria and number of exposed and unexposed |
| **Variables** | Ok, Page 5 Line 17-28, Section methods, Paragraph Statistical analysis | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
| **Data sources/ measurement** | Ok, Page 3 Line 17-Page 4 Line 2, Section methods, Paragraph Patients and treatment | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
| **Bias** | Ok, Page 5 Line 17-28, Section methods, Paragraph Statistical analysis | Describe any efforts to address potential sources of bias |
| **Study size** | Ok, Page 5 Line 17-28, Section methods, Paragraph Statistical analysis | Explain how the study size was arrived at |
| **Quantitative variables** | Ok, Page 5 Line 17-28, Section methods, Paragraph Statistical analysis | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| **Statistical methods** | Ok, Page 5 Line 17-28, Section methods, Paragraph Statistical analysis | *(a)* Describe all statistical methods, including those used to control for confounding  
* (b) Describe any methods used to examine subgroups and interactions  
* (c) Explain how missing data were addressed  
* (d) If applicable, explain how loss to follow-up was handled |
### Results

| Participants | Ok, Page 5 Line 32-Page 6 Line 4, Section results, Paragraph ## Patient demographics and OS |
|--------------|------------------------------------------------------------------------------------------------------------------|
| (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
| (b) Give reasons for non-participation at each stage |
| (c) Consider use of a flow diagram |

| Descriptive data | Ok, Page 5 Line 32-Page 6 Line 4, Section results, Paragraph ## Patient demographics and OS |
|------------------|------------------------------------------------------------------------------------------------------------------|
| (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders |
| (b) Indicate number of participants with missing data for each variable of interest |
| (c) Summarise follow-up time (eg, average and total amount) |

| Outcome data | Ok, Page 6 Line 6-17, Section results, Paragraph ## Patterns of first failure |
|--------------|--------------------------------------------------------------------------------|
| Report numbers of outcome events or summary measures over time |

| Main results | Ok, Page 6 Line 6-17, Section results, Paragraph ## Patterns of first failure |
|--------------|--------------------------------------------------------------------------------|
| (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |
| (b) Report category boundaries when continuous variables were categorized |
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |

| Other analyses | Ok, Page 6 Line 19-32, Section results, Paragraph ## Association between lymphopenia during radiotherapy and radiation target volumes |
|----------------|------------------------------------------------------------------------------------------------------------------|
| Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses |

### Discussion

| Key results | Ok, Page 7 Line 1-8, Section discussion, Paragraph 1 |
|-------------|-----------------------------------------------------|
| Summarise key results with reference to study objectives |

| Limitations | Ok, Page 9 Line 2-9, Section discussion, Paragraph 5 |
|-------------|-----------------------------------------------------|
| Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |

| Interpretation | Ok, Page 7 Line 9-Page 8 Line 23, Section discussion, Paragraph 2-3 |
|----------------|---------------------------------------------------------------------|
| Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |

| Generalisability | Ok, Page 8 Line 24-Page 9 Line 15, Section discussion, Paragraph 4-6 |
|------------------|---------------------------------------------------------------------|
| Discuss the generalisability (external validity) of the study results |

### Other information

| Funding | Ok, Page 9 Line 20-21, Section Funding |
|---------|----------------------------------------|
| Give the source of funding and the role of the funders for the present study and, if applicable, for the
Please notice that in this study, specific data from three large cohort studies have been used to determine the magnitude of dengue underrecognition in the two countries based on cases reported in the national surveillance systems. Therefore, in the methods and the result section we focused on variables/analyses relevant to this specific research question and not on all outcome parameters of the three cohort studies. Details on the analysis of further outcome parameters of the cohort studies have been published previously or are currently under consideration for publication elsewhere, references are provided in the text.

Article Information: http://dx.doi.org/10.21037/tlcr-20-523

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.